nepafenac has been researched along with Diabetic Retinopathy in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akpolat, Ç; Çekiç, O; Evliyaoğlu, F; Kurt, MM; Nuri Elçioğlu, M | 1 |
| Fong, DS; Modjtahedi, BS | 1 |
| Jonna, G; Kim, SJ | 1 |
| Grzybowski, A; Kanclerz, P | 1 |
| Almukhtar, TH; Baker, CW; Bressler, NM; Elman, MJ; Friedman, SM; Glassman, AR; Jampol, LM; Maker, MP; Melia, M | 1 |
| Mukesh, B; Pollack, A; Reiser, H; Sager, D; Singh, RP; Staurenghi, G | 1 |
| Adewale, A; Alpern, L; Cervantes-Coste Cervantes, G; Jaffe, GJ; Jong, K; Lehmann, R; Martel, J; Modi, S; Pollack, A; Singh, RP; Staurenghi, G; Svoboda, L; Tsorbatzoglou, A | 1 |
| Ball, SL; Bingaman, DP; Du, Y; Jamison, JA; Kern, TS; Kim, M; Miller, CM; Mohr, S; Zheng, L | 1 |
| Callanan, D; Gainey, S; Hariprasad, SM; He, YG; Warren, K | 1 |
4 trial(s) available for nepafenac and Diabetic Retinopathy
| Article | Year |
|---|---|
Retinal Vascular Caliber Changes After Topical Nepafenac Treatment for Diabetic Macular Edema.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Diabetic Retinopathy; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Macular Edema; Male; Middle Aged; Phenylacetates; Prospective Studies; Retinal Vessels; Tomography, Optical Coherence; Visual Acuity | 2018 |
Topical nepafenec in eyes with noncentral diabetic macular edema.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Macular Edema; Male; Middle Aged; Ophthalmic Solutions; Phenylacetates; Retina; Tomography, Optical Coherence; Visual Acuity | 2015 |
Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Cataract Extraction; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Macular Edema; Male; Middle Aged; Ophthalmic Solutions; Phenylacetates; Postoperative Complications; Treatment Outcome | 2017 |
Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy: Results of 2 Randomized Phase 3 Studies.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benzeneacetamides; Cataract; Diabetic Retinopathy; Double-Blind Method; Female; Humans; Lens Implantation, Intraocular; Macular Edema; Male; Middle Aged; Ophthalmic Solutions; Phacoemulsification; Phenylacetates; Postoperative Care; Prospective Studies; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2017 |
5 other study(ies) available for nepafenac and Diabetic Retinopathy
| Article | Year |
|---|---|
Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
Topics: Benzeneacetamides; Cataract; Cataract Extraction; Diabetic Retinopathy; Humans; Phenylacetates | 2018 |
Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: results of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
Topics: Benzeneacetamides; Cataract; Cataract Extraction; Diabetic Retinopathy; Humans; Phenylacetates | 2018 |
Re: Singh et al.: Nepafenac 0.3% after cataract surgery in patients with diabetic retinopathy: result of 2 randomized phase 3 studies (Ophthalmology. 2017;124:776-785).
Topics: Benzeneacetamides; Cataract; Cataract Extraction; Diabetic Retinopathy; Humans; Phenylacetates | 2018 |
Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Benzeneacetamides; Caspase 3; Caspase 6; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dinoprostone; Evoked Potentials, Visual; Inflammation; Male; Matrix Metalloproteinase 2; Nitric Oxide; Ophthalmic Solutions; Phenylacetates; Random Allocation; Rats; Rats, Inbred Lew; Retina; Retinal Vessels; Streptozocin; Superoxides; Vascular Endothelial Growth Factors | 2007 |
Cystoid and diabetic macular edema treated with nepafenac 0.1%.
Topics: Aged; Benzeneacetamides; Cataract Extraction; Diabetic Retinopathy; Female; Humans; Lenses, Intraocular; Macular Edema; Male; Phenylacetates; Steroids; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2007 |